Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Impact of Maraviroc, a ART CCR5 inhibitor, on the intensification of immune function in HIV-1
infected subjects receiving immunisation with novel antigens
The purpose of the study is to investigate the impact of adding Maraviroc (an anti-HIV agent)
to a participant's normal HIV medication, on immune function. As part of the study
participants will also receive three different vaccinations and a skin test. The study will
also look at whether Maraviroc influences the body's response to these.
The vaccines are given to stimulate the body's immune system, so we can therefore evaluate
the impact that Maraviroc has on this.
The duration of the study will be just over 24 weeks plus a screening period up to 4 weeks
prior to the start of the study.